Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1800 of 2873 entries
View as:

ProvoxLife Adoption Trends for Heat-Moisture Exchanger

Phase: N/A Priority: Normal
NCT ID: NCT05036330 Org: User:
Start: 05/21/21 End: 02/02/27 Due: 02/02/28

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT04239989 Org: User:
Start: 10/08/21 End: 05/31/25 Due: 05/31/26

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03896269 Org: User:
Start: 05/14/19 End: 12/31/27 Due: 12/31/28

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase: N/A Priority: Normal
NCT ID: NCT01552434 Org: User:
Start: 03/16/12 End: 03/31/26 Due: 03/31/27

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05053750 Org: User:
Start: 12/14/21 End: 02/02/27 Due: 02/02/28

Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT00652574 Org: User:
Start: 03/12/08 End: 10/07/22 Due: 10/07/23

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT04216563 Org: User:
Start: 07/29/20 End: 03/17/25 Due: 03/17/26

Caregiver Assessments of the Quality of Home Hospice Care

Phase: N/A Priority: Normal
NCT ID: NCT00895024 Org: User:
Start: 04/30/09 End: 09/28/20 Due: 09/28/21

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT04553757 Org: User:
Start: 07/08/20 End: 12/30/25 Due: 12/30/26

Stereotactic Liver Ablation Assisted With Intra-Arterial CT Hepatic Arteriography and Ablation Confirmation Software Assessment (STEREOLAB)

Phase: N/A Priority: Normal
NCT ID: NCT05361551 Org: User:
Start: 02/21/23 End: 08/31/26 Due: 08/31/27

Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01269190 Org: User:
Start: 12/30/10 End: 12/31/25 Due: 12/31/26

Sintilimab in Cancer of Unknown Primary

Phase: N/A Priority: Normal
NCT ID: NCT05024968 Org: User:
Start: 08/26/21 End: 04/03/25 Due: 04/03/26

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03074513 Org: User:
Start: 03/03/17 End: 09/30/25 Due: 09/30/26

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00253318 Org: User:
Start: 11/01/05 End: 04/30/12 Due: 04/30/13

Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems

Phase: N/A Priority: Normal
NCT ID: NCT06373354 Org: User:
Start: 10/18/24 End: 12/31/27 Due: 12/31/28

PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03965481 Org: User:
Start: 05/12/18 End: 04/30/27 Due: 04/30/28

Mindfulness Based Couples Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02349217 Org: User:
Start: 01/23/15 End: 08/01/22 Due: 08/01/23

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05039736 Org: User:
Start: 02/24/23 End: 05/03/23 Due: 05/03/24

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04435691 Org: User:
Start: 07/28/20 End: 03/25/25 Due: 03/25/26

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Phase: N/A Priority: Normal
NCT ID: NCT03307616 Org: User:
Start: 10/04/17 End: 10/31/25 Due: 10/31/26

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00477412 Org: User:
Start: 04/03/07 End: 10/28/20 Due: 10/28/21

Controlled Trial of Acupuncture to Prevent Radiation-Induced Xerostomia

Phase: N/A Priority: Normal
NCT ID: NCT01266044 Org: User:
Start: 12/09/11 End: 12/31/26 Due: 12/31/27

Neuropathic Pain in Survivors of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00535067 Org: User:
Start: 09/30/07 End: 11/30/13 Due: 11/30/14

Respiratory Tumor and Normal Tissue Motion

Phase: N/A Priority: Normal
NCT ID: NCT00415675 Org: User:
Start: 11/30/04 End: - Due: -

Survivorship in Lynch Syndrome Families

Phase: N/A Priority: Normal
NCT ID: NCT01126840 Org: User:
Start: 06/20/10 End: 09/19/22 Due: 09/19/23